JPRN-UMIN000006243Completed未知
Phase II study of carboplatin/pemetrexed/bevacizumab for non-squamous NSCLC with carcinomatous pleuritis (NEJ013A) - Phase II of CBDCA/PEM/BEV for NSCLC with carcinomatous pleuritis
orth-East Japan study group0 sites30 target enrollmentStarted: October 1, 2011Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. Clinically ineligible interstitial pneumonitis 2. Episode of hemoptysis 3. With brain metastasis, or tumor with large vessel invation or cavity formation 4. With active gastrointestinal ulcer 5. With severe comorbidities 6. With inadequate conditions judged by the attending physician
Investigators
Similar Trials
Completed
Phase 2
Phase II Study of Carboplatin+Pemetrexed+Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous non-small cell lung cancer(NSCLC).non-squamous non-small cell lung cancerJPRN-UMIN000003387Kansai Medical University Hirakata Hospital25
Completed
Not Applicable
Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer with EGFR Mutation (CJLSG0910)Advanced non-squamous non-small cell lung cancer with EGFR MutationJPRN-UMIN000003737Central Japan Lung Study Group32
Completed
Phase 2
Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer without EGFR Mutation (CJLSG0909)Advanced non-squamous non-small cell lung cancer without EGFR MutationJPRN-UMIN000003736Central Japan Lung Study Group52
Completed
Phase 2
Phase II study of carboplatin and pemetrexed plus bevacizumab after failure of first-line EGFR TKI therapy for non-small-cell lung cancer harboring EGFR mutation.on-squamous Non-small-cell Lung CancerJPRN-UMIN000004731Central Japan Lung Study Group27
Completed
Phase 2
Phase II study of Pemetrexed and Carboplatin plus Bevacizumab for advanced non-small cell lung cancernon-squamous non-small-cell lung cancerJPRN-UMIN000003680ippon Medical School Hospital26